Search Results

Abbott Vascular Expands XIENCE V USA Trial

August 13, 2009—Abbott Vascular (Santa Clara, CA) announced the expansion of its XIENCE V USA postapproval study designed to evaluate the safety and effectiveness of the Xience V everolimus-eluting coronary stent system in a real-world clinical setting out to 5 years.

Abbott Vascular Expands XIENCE V USA Trial to Enroll Patients in Industry-Wide DAPT Trial

August 13, 2009—Abbott Vascular (Santa Clara, CA) announced the expansion of its XIENCE V USA postapproval study designed to evaluate the safety and effectiveness of the Xience V everolimus-eluting coronary stent system in a real-world clinical setting out to 5 years.

FDA Approves TriReme's Glider PTCA Catheter

May 23, 2012—TriReme Medical, Inc. (Pleasanton, CA) announced approval by the US Food and Drug Administration (FDA) of the company's Glider percutaneous transluminal coronary angioplasty (PTCA) catheter, indicated for treating the stenotic portion of coronary arteries or bypass grafts to improve myocardial perfusion.

Abbott Vascular Presents Xience V Safety Data

May 25, 2010—Abbott Vascular (Santa Clara, CA) announced that two late-breaking clinical trials presented at the EuroPCR 2010 conference in Paris reinforced clinical data supporting the company's Xience V everolimus-eluting coronary stent system.

SCAI Conducts First Match Day for Interventional Cardiology Fellowship Placement

December 5, 2024—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the completion of the first Interventional Cardiology Match on December 4 (“Match Day”).

Expanded Data Presented From Abbott's MitraClip Postapproval Registry

April 30, 2018—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the presentation of 1-year findings from the postapproval registry evaluating the safety and efficacy of the MitraClip (Abbott Structural Heart) in a real-world, commercial setting.

US Pivotal Trial Begins for St. Jude Medical's Amplatzer Cardiac Plug to Prevent Stroke in AF Patients

March 8, 2013—St.

One-Year Small Vessel Data Published From Abbott Vascular's XIENCE V USA Postmarket Study

July 14, 2014—One-year results of real-world patients with small versus nonsmall vessel lesions in the XIENCE V USA study were published by James B. Hermiller, MD, et al in Catheterization and Cardiovascular Interventions (2014;84:7–16).

Benefits and Risks of Extended DAPT After EES Studied

January 25, 2016—Findings from a study of dual-antiplatelet therapy that aimed to characterize outcomes for everolimus-eluting stent (EES)–treated patients according to treatment with continued thienopyridine plus aspirin versus aspirin alone at 12 to 30 months after stenting were published by James B. Hermiller, MD, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2016;9:138–147).

Four-Year Postmarket Trial Results Support Abbott Vascular's Xience V EES in Bifurcation Lesions

September 28, 2015—Four-year results from the XIENCE V USA study of real-world patients with bifurcation lesions (BIF) receiving Abbott Vascular’s Xience V everolimus-eluting stents (EES) were published online ahead of print by James B. Hermiller, MD, et al in Catheterization and Cardiovascular Interventions.

Simple Score Shown to Predict Early and Late Mortality After TAVR

July 18, 2016—Findings from a study that analyzed patients from the Medtronic CoreValve United States Pivotal Trial program were used to develop a simple scoring system that incorporates standard and novel predictor variables after transcatheter aortic valve replacement (TAVR).

Sunil V. Rao, MD, Named 2022-2023 President of SCAI

May 24, 2022—Sunil V. Rao, MD, FSCAI was recently named the 2022-2023 President of the Society for Cardiovascular Angiography & Interventions (SCAI). His appointment was announced at SCAI’s 2022 Scientific Sessions held May 19-22 in Atlanta, Georgia.